The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: a review.

Sachin M. Shridharani, Michael Magarakis, Paul Manson, Navin K Singh, Basak Basdag, Gedge David Rosson

Research output: Contribution to journalArticle

Abstract

The management of keloids and hypertrophic scars continues to challenge health-care providers. Though both forms of pathologic scarring are distinct entities at the macro and microscopic level, their etiologies and treatment are often similar. Potential treatment approaches are progressing, and combinations of treatment options have been proposed in the literature with promising outcomes. The treatment evolution has reached a level where molecular therapeutic modalities are being investigated. Currently, no gold standard treatment exists. Overall success rates and patient satisfaction seem to be slowly climbing, but additional investigational studies must continue to be performed. Several studies have investigated antineoplastic agents, and there seems to be a marked improvement in rates of recurrence, patient satisfaction, and overall quality of scar when these agents are used. Intralesional injection and/or wound irrigation with interferon-a2b, interferon-g, mitomycin-C, bleomycin, or 5-fluorouracil seems to have a positive effect on the reduction of pathologic scars. There is mounting evidence that these drugs used alone or in combination therapy, have the potential to be an integral part of the treatment paradigm for hypertrophic scars and keloids.

Original languageEnglish (US)
Pages (from-to)355-361
Number of pages7
JournalAnnals of Plastic Surgery
Volume64
Issue number3
StatePublished - Mar 2010

Fingerprint

Hypertrophic Cicatrix
Keloid
Antineoplastic Agents
Cicatrix
Therapeutics
Patient Satisfaction
Interferons
Intralesional Injections
Bleomycin
Mitomycin
Fluorouracil
Health Personnel
Recurrence
Wounds and Injuries

ASJC Scopus subject areas

  • Surgery

Cite this

The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars : a review. / Shridharani, Sachin M.; Magarakis, Michael; Manson, Paul; Singh, Navin K; Basdag, Basak; Rosson, Gedge David.

In: Annals of Plastic Surgery, Vol. 64, No. 3, 03.2010, p. 355-361.

Research output: Contribution to journalArticle

@article{b29305120f7a4c609e5c11fbc1127b02,
title = "The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: a review.",
abstract = "The management of keloids and hypertrophic scars continues to challenge health-care providers. Though both forms of pathologic scarring are distinct entities at the macro and microscopic level, their etiologies and treatment are often similar. Potential treatment approaches are progressing, and combinations of treatment options have been proposed in the literature with promising outcomes. The treatment evolution has reached a level where molecular therapeutic modalities are being investigated. Currently, no gold standard treatment exists. Overall success rates and patient satisfaction seem to be slowly climbing, but additional investigational studies must continue to be performed. Several studies have investigated antineoplastic agents, and there seems to be a marked improvement in rates of recurrence, patient satisfaction, and overall quality of scar when these agents are used. Intralesional injection and/or wound irrigation with interferon-a2b, interferon-g, mitomycin-C, bleomycin, or 5-fluorouracil seems to have a positive effect on the reduction of pathologic scars. There is mounting evidence that these drugs used alone or in combination therapy, have the potential to be an integral part of the treatment paradigm for hypertrophic scars and keloids.",
author = "Shridharani, {Sachin M.} and Michael Magarakis and Paul Manson and Singh, {Navin K} and Basak Basdag and Rosson, {Gedge David}",
year = "2010",
month = "3",
language = "English (US)",
volume = "64",
pages = "355--361",
journal = "Annals of Plastic Surgery",
issn = "0148-7043",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars

T2 - a review.

AU - Shridharani, Sachin M.

AU - Magarakis, Michael

AU - Manson, Paul

AU - Singh, Navin K

AU - Basdag, Basak

AU - Rosson, Gedge David

PY - 2010/3

Y1 - 2010/3

N2 - The management of keloids and hypertrophic scars continues to challenge health-care providers. Though both forms of pathologic scarring are distinct entities at the macro and microscopic level, their etiologies and treatment are often similar. Potential treatment approaches are progressing, and combinations of treatment options have been proposed in the literature with promising outcomes. The treatment evolution has reached a level where molecular therapeutic modalities are being investigated. Currently, no gold standard treatment exists. Overall success rates and patient satisfaction seem to be slowly climbing, but additional investigational studies must continue to be performed. Several studies have investigated antineoplastic agents, and there seems to be a marked improvement in rates of recurrence, patient satisfaction, and overall quality of scar when these agents are used. Intralesional injection and/or wound irrigation with interferon-a2b, interferon-g, mitomycin-C, bleomycin, or 5-fluorouracil seems to have a positive effect on the reduction of pathologic scars. There is mounting evidence that these drugs used alone or in combination therapy, have the potential to be an integral part of the treatment paradigm for hypertrophic scars and keloids.

AB - The management of keloids and hypertrophic scars continues to challenge health-care providers. Though both forms of pathologic scarring are distinct entities at the macro and microscopic level, their etiologies and treatment are often similar. Potential treatment approaches are progressing, and combinations of treatment options have been proposed in the literature with promising outcomes. The treatment evolution has reached a level where molecular therapeutic modalities are being investigated. Currently, no gold standard treatment exists. Overall success rates and patient satisfaction seem to be slowly climbing, but additional investigational studies must continue to be performed. Several studies have investigated antineoplastic agents, and there seems to be a marked improvement in rates of recurrence, patient satisfaction, and overall quality of scar when these agents are used. Intralesional injection and/or wound irrigation with interferon-a2b, interferon-g, mitomycin-C, bleomycin, or 5-fluorouracil seems to have a positive effect on the reduction of pathologic scars. There is mounting evidence that these drugs used alone or in combination therapy, have the potential to be an integral part of the treatment paradigm for hypertrophic scars and keloids.

UR - http://www.scopus.com/inward/record.url?scp=77649268530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649268530&partnerID=8YFLogxK

M3 - Article

C2 - 20179490

AN - SCOPUS:77649268530

VL - 64

SP - 355

EP - 361

JO - Annals of Plastic Surgery

JF - Annals of Plastic Surgery

SN - 0148-7043

IS - 3

ER -